- Home
- HTZ vs IBRX Comparison
HTZ vs IBRX Comparison
Compare HTZ & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTZ
- IBRX
- Stock Information
- Founded
- HTZ 1918
- IBRX 2014
- Country
- HTZ United States
- IBRX United States
- Employees
- HTZ N/A
- IBRX N/A
- Industry
- HTZ Rental/Leasing Companies
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HTZ Consumer Discretionary
- IBRX Health Care
- Exchange
- HTZ Nasdaq
- IBRX Nasdaq
- Market Cap
- HTZ 2.4B
- IBRX 2.3B
- IPO Year
- HTZ 1997
- IBRX N/A
- Fundamental
- Price
- HTZ $5.52
- IBRX $2.53
- Analyst Decision
- HTZ Sell
- IBRX Strong Buy
- Analyst Count
- HTZ 4
- IBRX 6
- Target Price
- HTZ $4.90
- IBRX $9.83
- AVG Volume (30 Days)
- HTZ 9.4M
- IBRX 10.3M
- Earning Date
- HTZ 11-04-2025
- IBRX 11-11-2025
- Dividend Yield
- HTZ N/A
- IBRX N/A
- EPS Growth
- HTZ N/A
- IBRX N/A
- EPS
- HTZ N/A
- IBRX N/A
- Revenue
- HTZ $8,614,000,000.00
- IBRX $56,600,000.00
- Revenue This Year
- HTZ N/A
- IBRX $629.94
- Revenue Next Year
- HTZ $2.52
- IBRX $109.91
- P/E Ratio
- HTZ N/A
- IBRX N/A
- Revenue Growth
- HTZ N/A
- IBRX 4227.22
- 52 Week Low
- HTZ $2.77
- IBRX $1.83
- 52 Week High
- HTZ $9.39
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- HTZ 34.06
- IBRX 47.77
- Support Level
- HTZ $6.49
- IBRX $2.42
- Resistance Level
- HTZ $7.12
- IBRX $2.75
- Average True Range (ATR)
- HTZ 0.47
- IBRX 0.13
- MACD
- HTZ -0.15
- IBRX -0.01
- Stochastic Oscillator
- HTZ 3.03
- IBRX 22.88
About HTZ Hertz Global Holdings Inc
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The Company maintain a substantial network of company-operated rental locations, a majority of which are in Europe, and have franchisees and partners that operate rental locations under brands. Geographical markets includes U.S., Europe, Pacific Asia, Middle East and Africa, Latin America.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.